106 related articles for article (PubMed ID: 16043352)
21. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
22. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.
Ellis WJ; Vessella RL; Buhler KR; Bladou F; True LD; Bigler SA; Curtis D; Lange PH
Clin Cancer Res; 1996 Jun; 2(6):1039-48. PubMed ID: 9816265
[TBL] [Abstract][Full Text] [Related]
24. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
26. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Nicholson B; Gulding K; Conaway M; Wedge SR; Theodorescu D
Clin Cancer Res; 2004 Dec; 10(24):8728-34. PubMed ID: 15623658
[TBL] [Abstract][Full Text] [Related]
27. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
Miyake H; Pollak M; Gleave ME
Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
[TBL] [Abstract][Full Text] [Related]
28. A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
Fokidis HB; Yieng Chin M; Ho VW; Adomat HH; Soma KK; Fazli L; Nip KM; Cox M; Krystal G; Zoubeidi A; Tomlinson Guns ES
J Steroid Biochem Mol Biol; 2015 Jun; 150():35-45. PubMed ID: 25797030
[TBL] [Abstract][Full Text] [Related]
29. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME; Goddard L; Smith C; Nicholson RI
Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
[TBL] [Abstract][Full Text] [Related]
30. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
[TBL] [Abstract][Full Text] [Related]
32. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer.
Carstens RP; Eaton JV; Krigman HR; Walther PJ; Garcia-Blanco MA
Oncogene; 1997 Dec; 15(25):3059-65. PubMed ID: 9444954
[TBL] [Abstract][Full Text] [Related]
33. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
[TBL] [Abstract][Full Text] [Related]
34. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft.
Kim D; Gregory CW; French FS; Smith GJ; Mohler JL
Am J Pathol; 2002 Jan; 160(1):219-26. PubMed ID: 11786415
[TBL] [Abstract][Full Text] [Related]
36. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
Patel BJ; Pantuck AJ; Zisman A; Tsui KH; Paik SH; Caliliw R; Sheriff S; Wu L; deKernion JB; Tso CL; Belldegrun AS
J Urol; 2000 Oct; 164(4):1420-5. PubMed ID: 10992426
[TBL] [Abstract][Full Text] [Related]
37. Androgen-independent expression of adrenomedullin and peptidylglycine alpha-amidating monooxygenase in human prostatic carcinoma.
Jiménez N; Abasolo I; Jongsma J; Calvo A; Garayoa M; van der Kwast TH; van Steenbrugge GJ; Montuenga LM
Mol Carcinog; 2003 Sep; 38(1):14-24. PubMed ID: 12949839
[TBL] [Abstract][Full Text] [Related]
38. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
39. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
40. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.
de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Krenning EP; de Jong M
J Nucl Med; 2007 Jan; 48(1):88-93. PubMed ID: 17204703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]